The NCI-60 Methylome and Its Integration into CellMiner.

A unique resource for systems pharmacology and genomic studies is the NCI-60 cancer cell line panel, which provides data for the largest publicly available library of compounds with cytotoxic activity (∼21,000 compounds), including 108 FDA-approved and 70 clinical trial drugs as well as genomic data, including whole-exome sequencing, gene and miRNA transcripts, DNA copy number, and protein levels. Here, we provide the first readily usable genome-wide DNA methylation database for the NCI-60, including 485,577 probes from the Infinium HumanMethylation450k BeadChip array, which yielded DNA methylation signatures for 17,559 genes integrated into our open access CellMiner version 2.0 (https://discover.nci.nih.gov/cellminer). Among new insights, transcript versus DNA methylation correlations revealed the epithelial/mesenchymal gene functional category as being influenced most heavily by methylation. DNA methylation and copy number integration with transcript levels yielded an assessment of their relative influence for 15,798 genes, including tumor suppressor, mitochondrial, and mismatch repair genes. Four forms of molecular data were combined, providing rationale for microsatellite instability for 8 of the 9 cell lines in which it occurred. Individual cell line analyses showed global methylome patterns with overall methylation levels ranging from 17% to 84%. A six-gene model, including PARP1, EP300, KDM5C, SMARCB1, and UHRF1 matched this pattern. In addition, promoter methylation of two translationally relevant genes, Schlafen 11 (SLFN11) and methylguanine methyltransferase (MGMT), served as indicators of therapeutic resistance or susceptibility, respectively. Overall, our database provides a resource of pharmacologic data that can reinforce known therapeutic strategies and identify novel drugs and drug targets across multiple cancer types. Cancer Res; 77(3); 601-12. ©2016 AACR.

[1]  P. Sen,et al.  Introduction to bivariate and multivariate analysis , 1981 .

[2]  M. Ehrlich,et al.  Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. , 1982, Nucleic acids research.

[3]  A. Bird,et al.  Number of CpG islands and genes in human and mouse. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Strouboulis,et al.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription , 1998, Nature Genetics.

[5]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[6]  J. Weinstein,et al.  Karyotypic complexity of the NCI-60 drug-screening panel. , 2003, Cancer research.

[7]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[8]  Ulrike Groemping,et al.  Relative Importance for Linear Regression in R: The Package relaimpo , 2006 .

[9]  A. Verma.  MGMT Gene Silencing and Benefit From Temozolomide in Glioblastoma , 2006 .

[10]  A. Feinberg,et al.  Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells , 2007, Molecular Cancer Therapeutics.

[11]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[12]  S A Forbes,et al.  The Catalogue of Somatic Mutations in Cancer (COSMIC) , 2008, Current protocols in human genetics.

[13]  M. Marra,et al.  Epigenetics and human disease. , 2009, The international journal of biochemistry & cell biology.

[14]  J. Weinstein,et al.  mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities , 2010, Molecular Cancer Therapeutics.

[15]  W. Reinhold,et al.  Genome-Wide mRNA and microRNA Profiling of the NCI 60 Cell-Line Screen and Comparison of FdUMP[10] with Fluorouracil, Floxuridine, and Topoisomerase 1 Poisons , 2010, Molecular Cancer Therapeutics.

[16]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[17]  J.,et al.  The New England Journal of Medicine , 2012 .

[18]  W. Reinhold,et al.  Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents , 2012, Proceedings of the National Academy of Sciences.

[19]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[20]  M. Stevens,et al.  Temozolomide: mechanisms of action, repair and resistance. , 2012, Current molecular pharmacology.

[21]  P. Meltzer,et al.  Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. , 2013, Cancer discovery.

[22]  P. Meltzer,et al.  The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. , 2013, Cancer research.

[23]  J. Weinstein,et al.  High Resolution Copy Number Variation Data in the NCI-60 Cancer Cell Lines from Whole Genome Microarrays Accessible through CellMiner , 2014, PloS one.

[24]  K. Kohn,et al.  Gene Expression Correlations in Human Cancer Cell Lines Define Molecular Interaction Networks for Epithelial Phenotype , 2014, PloS one.

[25]  G. Reifenberger,et al.  MGMT testing—the challenges for biomarker-based glioma treatment , 2014, Nature Reviews Neurology.

[26]  P. Meltzer,et al.  NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses , 2014, PloS one.

[27]  W. Reinhold,et al.  Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60 , 2015, Clinical Cancer Research.

[28]  P. Meltzer,et al.  SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma , 2015, Clinical Cancer Research.

[29]  C. Sander,et al.  Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. , 2015, DNA repair.

[30]  Joshua A. Bittker,et al.  Correlating chemical sensitivity and basal gene expression reveals mechanism of action , 2015, Nature chemical biology.

[31]  C. Zahnow,et al.  Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy. , 2016, Advances in cancer research.

[32]  Yan Zhang,et al.  Epigenetic Pattern on the Human Y Chromosome Is Evolutionarily Conserved , 2016, PloS one.

[33]  Junjie Chen,et al.  SLFN11 inhibits checkpoint maintenance and homologous recombination repair , 2016, EMBO reports.

[34]  W. Reinhold,et al.  Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs , 2015, Oncotarget.

[35]  Y. Pommier,et al.  Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition , 2016, Oncotarget.

[36]  G. Paré,et al.  DNA methylation analysis in constitutional disorders: Clinical implications of the epigenome , 2016, Critical reviews in clinical laboratory sciences.

[37]  Jun Wang,et al.  Analysis of a four generation family reveals the widespread sequence-dependent maintenance of allelic DNA methylation in somatic and germ cells , 2016, Scientific Reports.

[38]  C. Ponting,et al.  Parallel single-cell sequencing links transcriptional and epigenetic heterogeneity , 2015, Nature Methods.

[39]  Adam A. Margolin,et al.  Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity , 2018, Nature.